Additional Relevant Details G100 is Immune Design’s first product candidate generated from the GLAAS™ platform utilizing the Endogenous Antigen approach. It includes Glucopyranosyl Lipid A (GLA), a small synthetic molecule that selectively binds to the Toll-like Receptor-4 receptor. The accessibility of certain tumors makes them ideal for intra-tumoral dosing, and the use of minimally invasive skin lesion biopsy to determine changes in the tumor microenvironment following G100 treatment. Immune Design believes that when G100 is administered with mechanisms that kill, or lyse, tumor cells, it may cause dendritic cells near the lysed tumor to activate and capture the wide range of released endogenous tumor antigens. This may trigger a broad immune response against those newly-encountered antigens